A realistic price and the offer of risk-sharing could help alternative pricing agreements be more attractive to AMGROS, Denmark’s procurement agency for hospital medicines, according to the body’s CEO, Flemming Sonne. AMGROS wants to capitalize on industry’s growing interest in these agreements and ensure they are better able to help deliver high cost innovation to patients.
Denmark Takes A Deep Dive Into Improving Alternative Drug Pricing Agreements
The Danish procurement body for hospital medicines, AMGROS, wants to better understand how to make alternative pricing agreements work and is inviting companies to take part in “deep dive dialogue” to ensure industry proposals hit the mark.
More from Europe
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
More from Pricing Debate
• By
An HHS legal brief argues company lawsuits seeking immediate clearance to use rebates in 340B are premature and that the department has merely used a ‘measured approach’ in weighing the possibility. Past experience suggests otherwise, a pricing expert said.
• By
The government wants to raise the statutory scheme payment rate for newer branded medicines from 15.5% to 32.2%, after sales data for Q2 and Q3 2024 showed “higher than expected newer medicines sales growth.”
• By
Physician and TV personality Mehmet Oz, who is President Trump's nominee for CMS administrator, said he was instructed by President Trump to explore “every single way” the agency could lower drug costs.